{"id":9,"date":"2018-04-01T20:07:52","date_gmt":"2018-04-01T19:07:52","guid":{"rendered":"https:\/\/admin.innaxon.com\/?page_id=9"},"modified":"2024-06-26T18:18:08","modified_gmt":"2024-06-26T17:18:08","slug":"about-innaxon","status":"publish","type":"page","link":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/","title":{"rendered":"About Innaxon"},"content":{"rendered":"\n\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg\" alt=\"Innaxon 5\" itemprop=\"image\" height=\"563\" width=\"750\" title=\"Innaxon 5\" onerror=\"this.style.display='none'\"  \/>\n<h2>\n\t\tInnaxon\u00a0Therapeutics is\u00a0an early stage development company based at Science Creates in Bristol, United Kingdom.\n\t<\/h2>\n\t<p>Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae and Novo-Pyrexal\u00ae) and in-licensed small molecule inhibitors (IAXO\u2122 compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively. Innaxon continuously seeks further partnerships with academic, pharmaceutical and clinical research centres to harness innate immunity for therapeutic benefit in the field of vaccine adjuvants immuno(chemo)therapy anti-inflammatory agents<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Innaxon\u00a0Therapeutics is\u00a0an early stage development company based at Science Creates in Bristol, United Kingdom. Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae and Novo-Pyrexal\u00ae) and in-licensed small molecule inhibitors (IAXO\u2122 compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively. Innaxon continuously<\/p>\n<p><a class=\"more-link\" href=\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/\">Read More<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-full-width.php","meta":{"footnotes":""},"class_list":["post-9","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>About Innaxon - Innaxon Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"About Innaxon - Innaxon Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Innaxon\u00a0Therapeutics is\u00a0an early stage development company based at Science Creates in Bristol, United Kingdom. Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae and Novo-Pyrexal\u00ae) and in-licensed small molecule inhibitors (IAXO\u2122 compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively. Innaxon continuouslyRead More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/\" \/>\n<meta property=\"og:site_name\" content=\"Innaxon Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-26T17:18:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/\",\"url\":\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/\",\"name\":\"About Innaxon - Innaxon Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/admin.innaxon.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg\",\"datePublished\":\"2018-04-01T19:07:52+00:00\",\"dateModified\":\"2024-06-26T17:18:08+00:00\",\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/#primaryimage\",\"url\":\"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg\",\"contentUrl\":\"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg\",\"width\":750,\"height\":563},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/admin.innaxon.com\/#website\",\"url\":\"https:\/\/admin.innaxon.com\/\",\"name\":\"Innaxon Therapeutics\",\"description\":\"Targeting Innate Immunity For Therapeutic Benefit\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/admin.innaxon.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"About Innaxon - Innaxon Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/","og_locale":"en_GB","og_type":"article","og_title":"About Innaxon - Innaxon Therapeutics","og_description":"Innaxon\u00a0Therapeutics is\u00a0an early stage development company based at Science Creates in Bristol, United Kingdom. Innaxon&#8217;s in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin\u00ae and Novo-Pyrexal\u00ae) and in-licensed small molecule inhibitors (IAXO\u2122 compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively. Innaxon continuouslyRead More","og_url":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/","og_site_name":"Innaxon Therapeutics","article_modified_time":"2024-06-26T17:18:08+00:00","og_image":[{"url":"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/","url":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/","name":"About Innaxon - Innaxon Therapeutics","isPartOf":{"@id":"https:\/\/admin.innaxon.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/#primaryimage"},"image":{"@id":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/#primaryimage"},"thumbnailUrl":"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg","datePublished":"2018-04-01T19:07:52+00:00","dateModified":"2024-06-26T17:18:08+00:00","inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/admin.innaxon.com\/index.php\/about-innaxon\/#primaryimage","url":"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg","contentUrl":"https:\/\/admin.innaxon.com\/wp-content\/uploads\/2018\/04\/Innaxon-5.jpg","width":750,"height":563},{"@type":"WebSite","@id":"https:\/\/admin.innaxon.com\/#website","url":"https:\/\/admin.innaxon.com\/","name":"Innaxon Therapeutics","description":"Targeting Innate Immunity For Therapeutic Benefit","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admin.innaxon.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/pages\/9","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/comments?post=9"}],"version-history":[{"count":20,"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/pages\/9\/revisions"}],"predecessor-version":[{"id":801,"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/pages\/9\/revisions\/801"}],"wp:attachment":[{"href":"https:\/\/admin.innaxon.com\/index.php\/wp-json\/wp\/v2\/media?parent=9"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}